Single or multiple daily doses of aminoglycosides: A meta- analysis

BMJ

Volumn 312, Issue 7027, 1996, Pages 338-344

  Barza, Michael ^a   Ioannidis, John Pa ^a   Cappelleri, Joseph C ^a   Lau, Joseph ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT;

ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HUMAN; META ANALYSIS; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK; TREATMENT FAILURE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG ADMINISTRATION SCHEDULE; EAR DISEASES; HUMANS; KIDNEY DISEASES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 0030068231     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.312.7027.338     Document Type: Article

References (64)

1. Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335–339.
2. Nordstrom L, Lerner SA. Single daily dose therapy with aminoglycosides. J Hosp Infect 1991; 18(suppl A):117–29.
3. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991; 35: 399–405.
4. Rozdzinski E, Kern WV, Reichle A, Moritz T, Schmeiser T, Gaus W, et al. Once-daily versus thrice-daily dosing of netilmicin in combination with B-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993; 31: 585–598.
5. Klastersky J, Prevost JM, Meunier-Carpentier F, Daneau D, Gerard M. Comparative trial of single dose versus twice daily sisomicin in bacteriuric patients. J Clin Pharmacol 1977; 17: 520–528.
6. Galloe AM, Madsen LB, Graudal N, Kampmann JP. Aminoglycosides: single or multiple daily dosing? [letter]. Lancet 1993; 341: 1152.
7. Nordstrom L, Ringberg H, Cronberg S, Tjernstrom O, Walder M. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother 1990; 25: 159–173.
8. Bracken MB. Statistical methods for analysis of effects of treatment in overviews of randomised trials. In: SinclairJC,BrackenMB, eds. Effective care of the newborn infant. Oxford: Oxford University Press, 1992: 13–18.
9. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993; 2: 121–145.
10. Thompson SG. Controversies in meta-analysis: the case of the trials of serum cholesterol reduction. Stat Methods Med Res 1993; 2: 173–192.
11. Chalmers TC, Lau JL. Meta-analytic stimulus for changes in clinical trials. Stat Methods Med Res 1993; 2: 161–172.
12. Oakes M. The logic and role of meta-analysis in clinical research. Stat Methods Med Res 1993; 2: 147–160.
13. SAS Institute. SAS guide for personal computers. Version 6.03. Cary, NC: SAS Institute, 1988.
14. Hansen M, Achen F, Carstensen C, Coolidge J, Dahlager J, Frimodt-Moller N, et al. Once versus thrice-daily dosing of netilmicin in febrile immunocompromised patients: a randomized, controlled study of efficacy and safety. Journal of Drug Development 1988; 1(suppl 3):119–24.
15. Muijsken MA, Vreede RW, Van Dijk WC, Haverkom MJ, Kaufman L, Derde MP. A randomized clinical study of efficacy and safety of once daily versus conventional dosing of netilmicin in patients with severe infections. Journal of Drug Development 1988; 1(suppl 3):145–6.
16. Tulkens PM, Clerckx-Braun F, Donnez J, Ibrahim S, Kallay Z, Delmee M, et al. Safety and efficacy of aminoglycosides once-a-day: experimental data and randomized, controlled evaluation in patients suffering from pelvic inflammatory disease. Journal of Drug Development 1988; 1(suppl 3):71–82.
17. Hollender LF, Bahnini J, De Manzini N, Lau WY, Fan ST, Hermansyur K, et al. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections. J Antimicrob Chemother 1989; 23: 773–783.
18. Mauracher EH, Lau W-Y, Kartowisastro H, Ong K-H, Genato VX, Limson B, et al. Comparison of once-daily and thrice-daily netilmicin regimens in serious systemic infections: a multicenter study in six Asian countries. Clin Ther 1989; 11: 604–613.
19. Sturm AW. Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis 1989; 159: 931–937.
20. De Vries PJ, Verkooyen RP, Leguit P, Verbrugh HA. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis 1990; 9: 161–168.
21. Ter Braak EW, de Vries PJ, Bouter KP, van der Vegt SG, Dorrestein GC, Nortier JW, et al. Once-daily dosing regimen for aminoglycoside plus B-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1990; 89: 58–66.
22. Giamarellou H, Yiallouros K, Petrikkos G, Moschovakis E, Vavouraki E, Voutsinas D, et al. comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections. J Antimicrob Chemother 1991; 27(suppl C):73–79.
23. Marik PE, Lipman J, Kobilski S, Scribante J. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991; 28: 753–764.
24. Van der Auwera P, Meunier F, Ibrahim S, Kaufman L, Derde MP, Tulkens PM. Pharmacodynamic and toxicity of netilmicin (6 milligrams/kilograms/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother 1991; 35: 640–647.
25. Vigano A, Principi N, Brivio L, Tommasi P, Stasi P, Villa AD. Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children. Antimicrob Agents Chemother 1992; 36: 1499–503.
26. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584–593.
27. Gonzalez P, Aguado JM, Martin MA, Fernandez-Chacon T, Ortuno B. Oncedaily aminoglycoside dosing [letter]. Lancet 1993; 341: 895.
28. Maller R, Ahrne H, Holmen C, Nilsson LE, Smedjegard J. Once- versus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections. J Antimicrob Chemother 1993; 31: 939–948.
29. Vanhaeverbeek M, Siska G, Douchamps J, Herchuelz A. Comparison of the efficacy and safety of amikacin once or twice-a-day in the treatment of severe gram-negative infections in the elderly. Int J Clin Pharmacol Ther Toxicol 1993; 31: 153–156.
30. Gibson J, Johnson L, Snowdon L, Joshua D, Young G, MacLeod C, et al. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: a randomised trial. Int J Hematol 1993; 58: 63–72.
31. Mendes da Costa P, Kaufman L. Amikacin once daily plus metronidazole versus amikacin twice daily plus metronidazole in colorectal surgery. Hepatogastroenterology 1992; 39: 350–354.
32. Labovitz E, Levison ME, Kaye D. Single-dose daily gentamicin therapy in urinary tract infection. Antimicrob Agents Chemother 1974; 6: 465–470.
33. Powell SH, Thompson WL, Luthe MA, Stern RC, Grossniklaus DA, Bloxam DD, et al. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis 1983; 147: 918–930.
34. Cohen B, Saginur R, Clecner B, Mendelson J, Kavalec E. Double-blind comparative trial of once- vs twice-daily netilmicin therapy in severe acute urinary tract infections. Current Therapeutic Research 1985; 38: 880–884.
35. Vogelman B, Gudmundsoon S, Turnidge J, Leggett J, Craig WA. In vitro postantibiotic effect in a thigh injection in neutropenic mice. J Infect Dis 1988; 157: 287–298.
36. Gerber AU, Feller-Segessenmann C. In vitro assessment of in vitro killing patterns of Pseudomonas aeruginosa. J Antimicrob Chemother 1985; 15(suppl A):201–6.
37. Kapusnik JE, Hackbarth CJ, Chambers HF, Carpenter T, Sande MA. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental Pseudomonas pneumonia. J Infect Dis 1988; 158: 7–12.
38. Gerber AU. Comparison of once-daily versus thrice-daily human equivalent dosing of aminoglycosides: basic considerations and experimental approach. Journal of Drug Development 1988; 1(suppl 3):17–23.
39. Yourassowsky E, van dar Linden MP, Crokaert F. One shot of high-dose amikacin: a working hypothesis. Chemotherapy 1990; 36: 1–7.
40. Daikos GL, Jackson GG, Lolans VT, Livermore DM. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis 1990; 162: 414–420.
41. Daikos GL, Lolans VT, Jackson GG. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 1991; 35: 117–123.
42. Noone P, Parsons TMC, Pattison JR, Slack RCB, Garfield-Davies D, Hughes K. Experience in monitoring gentamicin therapy during treatment of serious Gram-negative sepsis. BMJ 1974; 1: 477–481.
43. Anderson ET, Young LS, Hewitt WL. Simultaneous antibiotic levels in “breakthrough” gram-negative rod bacteremia. Am J Med 1976; 61: 493–497.
44. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside levels with mortality in patients with Gram-negative bacteremia. J Infect Dis 1984; 149: 443–448.
45. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31: 1054–60.
46. Gerber AU, Kozak S, Segessenmann C, Fluckinger U, Bangerter T, Greter U. Once-daily versus thrice-daily administration of netilmicin in combination therapy of Pseudomonas aeruginosa infection in a man-adapted neutropenic animal model. Eur J Clin Microbiol Infect Dis 1989; 8: 233–237.
47. Mordenti JJ, Quintiliani R, Nightingale CH. Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model. J Antimicrob Chemother 1985; 15: 313–321.
48. Roosendaal R, Bakker-Woudenberg IAJ, Berghe-van Raffe M, Berg JCV, Michel MF. Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin, and ciprofloxacin on Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. Eur J Clin Microbiol Infect Dis 1989; 8: 878–887.
49. Bennett WM, Plamp CE, Gilbert DN, Parker RA, Porter GA. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis 1979; 140: 576–580.
50. Reiner NE, Bloxham DD, Thompson WL. Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J Antimicrob Chemother 1978; 4(suppl A):85–101.
51. Olier B, Viotte G, Morin JP, Fillastre JP. Influence of dosage regimen on experimental tobramycin nephrotoxicity. Chemotherapy 1983; 29: 385–394.
52. Herscovici L, Grise G, Thauvin C, Lemeland JF, Fillastre JP. Efficacy and safety of once daily versus intermittent dosing of tobramycin in rabbits with pyelonephritis. Scand J Infect Dis 1988; 20: 205–212.
53. Wood CA, Norton DR, Kohlhepp SJ, Kohnen PW, Porter GA, Houghton DC, et al. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis 1988; 158: 13–22.
54. Pechere JC, Bernard PA. Gentamicin ototoxicity can be avoided if a new therapeutic regimen is used. 24th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1984: (Abstract 484.)
55. Brummett RE. Ototoxicity of tobramycin, gentamicin, amikacin and sisomicin in the guinea pig. J Antimicrob Chemother 1978; 4(suppl A):73–83.
56. Davis RR, Brummett RE, Bendrick TW, Himes DL. Dissociation of maximum concentration of kanamycin in plasma and perilymph from ototoxic effects. J Antimicrob Chemother 1984; 14: 291–302.
57. Bamonte F, Dionisotti S, Gamba M, Ongini E, Arpini A, Melone G. Relation of dosing regimens to aminoglycoside ototoxicity: evaluation of auditory damage in the guinea pig. Chemotherapy 1990; 36: 41–50.
58. Aronoff GR, Pottratz ST, Brier ME, Walker NE, Fineberg NS, Glant MD, et al. Aminoglycoside accumulation kinetics in rat renal parenchyma. Antimicrob Agents Chemother 1983; 23: 74–78.
59. de Broe ME, Giuliano RA, Verpooten GA. Choice of drug and dosage regimen: two important risk factors for aminoglycoside nephrotoxicity. Am J Med 1986; 80(suppl 6B):115–8.
60. Tra Ba Huy P, Bernard P, Schacht J. Kinetics of gentamicin uptake and release in the rat: comparison of inner ear tissues and fluid with other organs. Journal of Clinical Investigation 1986; 77: 1492–500.
61. Tran Ba Huy P. Aminoglycoside ototoxicity: influence of dosage regimen on drug uptake, correlation between membrane binding a clinical feature. Journal of Drug Development 1988; 1(suppl 3):93–5.
62. Verpooten GA, Giuliano RA, Verbist L, Esterman G, de Broe ME. Oncedaily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989; 45: 22–27.
63. Feld R, Rachlis A, Tuffnell PG, Duncan I, Moran L, Pinfold P, et al. Empiric therapy for infections in patients with granulocytopenia: continuous vs. interrupted infusion of tobramycin plus cefamandole. Arch Intern Med 1984; 144: 1005–10.
64. McCormack JP, Jewesson PJ. A critical reevaluation of the “therapeutic range” of aminoglycosides. Clin Infect Dis 1992; 14: 320–339.